At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QNCX Quince Therapeutics, Inc.
Market Closed 05-29 16:00:00 EDT
1.15
-0.02
-1.71%
盘后1.16
+0.01+0.87%
19:59 EDT
High1.23Low1.15Vol710.42K
Open1.18D1 Closing1.17Amplitude6.84%
Mkt Cap22.49MTradable Cap21.81MTotal Shares19.56M
T/O847.28KT/O Rate3.75%Tradable Shares18.97M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Quince Therapeutics regains Nasdaq listing compliance after equity rises to $15.67 million
Reuters  ·  05-22
Quince Therapeutics regains Nasdaq listing compliance after equity rises to $15.67 million
Quince Therapeutics announces LAM-001 data
TIPRANKS  ·  05-18
Quince Therapeutics announces LAM-001 data
Quince Therapeutics acquires Orphai Therapeutics, terms undisclosed
TIPRANKS  ·  05-18
Quince Therapeutics acquires Orphai Therapeutics, terms undisclosed
Quince Therapeutics prices private placement raising up to $187 million
Reuters  ·  05-18
Quince Therapeutics prices private placement raising up to $187 million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
Reuters  ·  05-18
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
Quince Therapeutics acquires Orphai Therapeutics, adds inhaled rapamycin program LAM-001
Reuters  ·  05-18
Quince Therapeutics acquires Orphai Therapeutics, adds inhaled rapamycin program LAM-001
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
THOMSON REUTERS  ·  05-18
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline
Quince Therapeutics reports Phase 2a LAM-001 gains in PH-ILD patients
Reuters  ·  05-18
Quince Therapeutics reports Phase 2a LAM-001 gains in PH-ILD patients
Quince Therapeutics - Lam-001 Generally Well Tolerated in Phase 2a Study
THOMSON REUTERS  ·  05-18
Quince Therapeutics - Lam-001 Generally Well Tolerated in Phase 2a Study
Quince Therapeutics - Lam-001 Phase 2a in Ph-Ild Shows 67.4M 6Mwd Improvement, 33.9% Pvr Reduction at 24 Weeks
THOMSON REUTERS  ·  05-18
Quince Therapeutics - Lam-001 Phase 2a in Ph-Ild Shows 67.4M 6Mwd Improvement, 33.9% Pvr Reduction at 24 Weeks
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in Pah and Ph-Ild
THOMSON REUTERS  ·  05-18
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in Pah and Ph-Ild
Quince Therapeutics - Phase 2B Trial in Ph-Ild to Start Mid-2026, Topline Data Expected Q1 2028
THOMSON REUTERS  ·  05-18
Quince Therapeutics - Phase 2B Trial in Ph-Ild to Start Mid-2026, Topline Data Expected Q1 2028
Quince Therapeutics swings to Q1 net income of $35.91 million; operating loss narrows 2% to $14.59 million
Reuters  ·  05-12
Quince Therapeutics swings to Q1 net income of $35.91 million; operating loss narrows 2% to $14.59 million
Quince Therapeutics Inc expected to post a loss of $2.56 a share - Earnings Preview
Reuters  ·  05-08
Quince Therapeutics Inc expected to post a loss of $2.56 a share - Earnings Preview
Quince Therapeutics regains Nasdaq $1 minimum bid price compliance
Reuters  ·  04-29
Quince Therapeutics regains Nasdaq $1 minimum bid price compliance
Quince Therapeutics appoints June Bray to board as independent director
Reuters  ·  04-23
Quince Therapeutics appoints June Bray to board as independent director
Largest borrow rate increases among liquid names
TIPRANKS  ·  04-21
Largest borrow rate increases among liquid names
Quince Therapeutics announces annual shareholder meeting via webcast
Reuters  ·  04-18
Quince Therapeutics announces annual shareholder meeting via webcast
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
Reuters  ·  04-12
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
Quince Therapeutics trading halted, news pending
TIPRANKS  ·  04-11
Quince Therapeutics trading halted, news pending

Introduction

Company Name.
Quince Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Issue price:
--